Streetbeat News

Partnerships

REGN

Medison Pharma has entered into an agreement with Regeneron Pharmaceuticals to commercialize Libtayo, a cancer treatment drug, in multiple countries. This partnership could potentially expand the market reach of Libtayo and enhance its sales, benefiting Regeneron's revenue stream and market presence in the oncology sector.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:32 pm

PLUR

Pluri has announced the launch of PluriCDMO, a new business division focused on providing cell therapy manufacturing services. This move positions Pluri as a Contract Development and Manufacturing Organization (CDMO) within the $5.2 billion cell and gene therapy market. The new division aims to assist companies in developing and manufacturing transformative cell therapies.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:28 pm

BABA

BIDU

NVDA

Alibaba Group Holding Limited (NYSE:BABA) stock is trading lower due to reports of reducing orders for Nvidia Corp's (NASDAQ:NVDA) chips. This shift is attributed to Chinese companies' growing interest in local options and in-house developments. Major Chinese firms like Baidu Inc (NASDAQ:BIDU) and ByteDance are also turning to domestic chip producers such as Huawei Technologies. Despite this, Alibaba.com showcased its machine learning advancements at CES in Las Vegas, indicating a commitment to global expansion. Alibaba's stock value decreased by over 34% last year, and BABA shares were down 2.44% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

January 08, 2024 | 12:26 pm

OPCH

PLTR

Palantir Technologies Inc. (PLTR) has entered into a multi-year commercial partnership with Option Care Health Inc. (OPCH). Under this partnership, Option Care Health will utilize Palantir's Artificial Intelligence Platform to enhance various operational aspects such as nurse scheduling, patient onboarding, purchasing optimization, and supply chain execution. The collaboration aims to improve patient outcomes and increase efficiency within Option Care Health's services.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:21 pm

AZN

CGEN

Compugen will receive a $10M milestone payment as AstraZeneca begins Phase 3 trials of Rilvegostomig for Biliary Tract Cancer, following the dosing of the first patient.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:21 pm

MREO

Mereo BioPharma Group plc (NASDAQ:MREO) has reiterated its previous cash runway guidance, stating that its current cash reserves are expected to fund operations into 2026. The company provided updates on its pipeline programs, including the Phase 3 Orbit Study and Cosmic Study of setrusumab for Osteogenesis Imperfecta, and the design alignment for a Phase 3 study of alvelestat in AATD-LD following FDA interactions. Additionally, Mereo announced a global licensing deal for the development and commercialization of leflutrozole.

Portfolio Pulse from Charles Gross

January 08, 2024 | 12:18 pm

IMNM

ZNTL

Immunome and Zentalis Pharmaceuticals have entered into an exclusive, worldwide license agreement. Zentalis will receive an initial payment of $35 million in cash and Immunome common stock, with the potential to earn up to $275 million in milestone payments for ZPC-21 and the platform technology. Additionally, Zentalis is set to receive mid-to-high single-digit royalties.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:15 pm

AWI

Armstrong World Industries, Inc. (AWI) has formed a strategic partnership with McKinstry by investing in Overcast Innovations, which specializes in integrated building solutions. This partnership aims to leverage Armstrong's ceiling solutions and market reach to accelerate Overcast's growth, addressing challenges such as labor shortages and the need for energy-efficient designs in the construction industry.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:15 pm

JOBY

Joby Aviation, Inc. has partnered with Clay Lacy Aviation to install the first electric air taxi charger at John Wayne Airport in Southern California. This development is a step towards the commercialization of Joby's electric air taxis.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:14 pm

HLVX

HilleVax and Kangh have entered into an exclusive license agreement for the development and commercialization of a hexavalent VLP norovirus vaccine candidate outside of China. This partnership could potentially enhance HilleVax's product pipeline and market reach, while providing Kangh with licensing revenues and a share in the global market, excluding China.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:13 pm